Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

The addition of pembrolizumab to chemoradiotherapy improved PFS and OS for women with high-risk, locally advanced cervical cancer. The safety profile appeared consistent with that of the ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary ...